CN1491645A - Compound preparation for improving acute wound heeling for local use - Google Patents
Compound preparation for improving acute wound heeling for local use Download PDFInfo
- Publication number
- CN1491645A CN1491645A CNA031329640A CN03132964A CN1491645A CN 1491645 A CN1491645 A CN 1491645A CN A031329640 A CNA031329640 A CN A031329640A CN 03132964 A CN03132964 A CN 03132964A CN 1491645 A CN1491645 A CN 1491645A
- Authority
- CN
- China
- Prior art keywords
- goods
- aminoacid
- local application
- arginine
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to one composition for local application to promote the healing of acute wound and improve healing quality. The composition contains at least one kind of pharmaceutically acceptable excipient, additive compound, amino acid, at least one antimicrobial compound, at least one antiphlogistic and analgetic compound, and at least one compound for surficial narcosis. It is prepared into different products, such as emulsion, gel, film, liposome and spray, for local application.
Description
Technical field
The present invention relates to medical technical field, is the healing of a kind of promotion acute wounds (trauma wounds, operative incision, burn wound), and improves the method for healing quality.
Background of invention
Wound delayed healing, disunion or the acute wounds such as bad that heals are clinical common and stubborn problems.The method of curing this class wound in recent years receives great concern.For example, Chinese application number 96198773.1＜the contain gel preparation of somatomedin 〉, Chinese application number 98813949.9＜application protease inhibitors for treating skin wounds 〉.The existing medicine that is used for acute wounds (trauma wounds, operative incision) still can not effectively play accelerating wound and shorten the effect of healing time, and accelerating its healing is a clinical difficult problem that needs solution.The inventor finds under study for action: add the healing that amino acidses such as arginine or wound topical application arginine all can promote wound in the diet.
Aminoacid such as arginine, it is synthetic to participate in protein in body, and the stimulating growth hormone discharges, and wound healing is had Nutrition.Amino-acid compounds such as arginine are the unique sources of NO in the body, can expand local vascular, improve the blood deposition condition of wound.Amino-acid compounds such as arginine also can be used as the reinforcing agent of exempting from service, and increase the T cell function of exempting from service, and improve local anti-infection ability.
Up to now, also do not provide a suitable amino acid whose drug-supplying system that is used for the treatment of the injury place.Especially, expectation finds one can control aminoacid and discharge and adhere to or keep the drug-supplying system of considerable time with time of contact of increasing aminoacid and injury place at the injury place to the injury place.The present invention just is being based on this starting point and is designing.
Summary of the invention
This part is based on a kind of Therapeutic Method and goods of new processing wound, the wound healing enhancer compositions of topical application.In order to reach these purposes, according to an aspect of the present invention, local application one seed amino acid promotes the healing and the healing quality of wound.
The local application amino acids
The indefiniteness example of amino acids comprises arginine, ornithine etc.This method comprises by patients ' demand uses a kind of step of the therapeutic agent that contains aminoacid (comprising one of the analog of arginine, ornithine etc. or their derivant or their any salt etc.) of effective dose to it, wherein this aminoacid is locally applied to wound, it is synthetic that this amino acid participates in protein in body, the stimulating growth hormone discharges, and wound healing is had Nutrition.Amino-acid compounds such as arginine are the unique sources of NO in the body, expand local vascular, improve the blood deposition condition of wound.Amino-acid compounds such as arginine also can be used as the reinforcing agent of exempting from service, and increase the T cell function of exempting from service, and improve local anti-infection ability.Use aminoacid in wound surface, medicament can directly act on blood vessel, the muscle of wound.
Local application antibiotic, anti-inflammatory agent and topical anesthetic cream
Acute wounds easy infection antibacterial causes inflammation, thereby delays the healing of wound.Therapeutic Method also comprises local application antibiotic, anti-inflammation analgesia medicine or topical anesthetic cream or the two.But these medicament combating microorganisms, the inflammatory exudation of wound surface alleviates the pain of wound, helps wound surface and uses the repair of aminoacid to wound.The first-selected sulfonamides antibiotics of the indefiniteness example of local application antiviral antibiotic also comprises other classification antibiotic such as aminoglycosides, Macrolide.The indefiniteness example of local application anti-inflammatory agent or topical anesthetic cream comprises nonsteroidal antiinflammatory drugs such as fragrant that acids, indoles, as diclofenac, piroxicam etc., topical anesthetic cream lignocaine, marcaine, mepivacaine, dyclonine etc., and some plant extract AIDs, as: β-Sodium Aescinate etc.
On the one hand, feature of the present invention is the method that a kind of treatment has the patient of superficial cut, it is characterized in that, described method comprises a certain amount of aminoacid of local application, thereby strengthens the healing of described wound.Aminoacid can be arginine, ornithine, leucine etc.This method also comprises uses a certain amount of anti-inflammation analgesia medicine, comprises nonsteroidal anti-inflammatory analgetics such as fragrant that acids, indoles.This method also comprises uses a certain amount of topical anesthetic cream, as lignocaine, marcaine, mepivacaine, dyclonine etc.
Another feature of the present invention is a kind of compositions that contains aminoacid, antibiotic, anti-inflammation analgesia medicine, topical anesthetic cream.
On the other hand, feature of the present invention is a kind of goods, comprises packaging material and a certain amount of aminoacid.Described packaging material contain a label, and this label shows that described aminoacid is to be used for the treatment of the patient with acute wounds, and the described aminoacid of the described amount of local application is to promote the healing of described wound.These goods also comprise a certain amount of anti-inflammation analgesia medicine, topical anesthetic cream.
The indefiniteness example of these goods comprises that in one embodiment these goods are breast (ointment) agent.In second embodiment, these goods are gel.In the 3rd embodiment, these goods are spray.In the 4th embodiment, these goods are liposome.
The embodiment that below lists is used to illustrate the present invention.The present invention is not these embodiment limitations.
The specific embodiment
Embodiment 1
The arginine liposome
Liposome prepares according to the present invention.With synthetic two palmityls-DL-α phosphatidylcholine (DPPC) two myristoyl lecithin (DMPC) of pharmaceutical grade respectively with two spermaceti phosphoric acid fat (DCP) or stearmide (SA) (8: 1) mix homogeneously in molar ratio.Take out 10
-4This mixture of mol/L places in the round-bottomed flask, and is with the dissolving of 20ml chloroform, on rotary film evaporator, to being dry thin layer, standby in 45 ℃ of vacuum evaporation.Get NaH
2PO
4H and Na
2HPO
4Be made into the buffer (PBS) of 0.01mol/L pH7 with distilled water.Other gets arginase 12 0mg, sulfadiazine 5%, and dyclonine 250mg is dissolved among the 25ml PBS.The PBS that will contain arginine, dyclonine slowly has been added in the lipid membrane flask, slowly stirs, and this suspension is in 4 ℃～6 ℃ placements 4 days, centrifugal, promptly.
Embodiment 2
Arginine W/O gel
The W/O gel prepares according to the present invention.With spermol, eumulgin B3 and isopropyl palmitate, the oil mixture of silver sulfadiazine is heated to 70 ℃, buffer is dissolved in 80 ℃ the deionized water, under gentle agitation arginine, diclofenac is dissolved in the buffer.This buffer is added in the surfactant mixture, jumps a queue, be incubated in 75 ℃ until forming uniform molten mixture, under shaking, be chilled to room temperature, promptly.
Claims (17)
1. a treatment has the patient's of acute superficial cut method, it is characterized in that described method comprises the aminoacid of the effective Wound healing and bone regeneration amount of local application, thereby promotes the healing of described wound.
2. the method for claim 1 is characterized in that, described aminoacid is arginine.Wherein arginine can comprise one of arginine analog or their derivant or their any salt.
3. the method for claim 1 is characterized in that, described aminoacid is ornithine.Wherein ornithine can comprise one of ornithine analog or their derivant or their any salt.
4. the method for claim 1 is characterized in that, described aminoacid is leucine.Wherein leucine can comprise one of leucine analog or their derivant or their any salt.
5. the method for claim 1 is characterized in that, described aminoacid is glutamic acid.Wherein glutamic acid can comprise one of glutamic acid analog or their derivant or their any salt.
6. the method for claim 1 is characterized in that, the anti-inflammatory agent of local application effective dose.
7. the method for claim 1 is characterized in that, the topical anesthetic cream of local application effective dose.
8. the method for claim 1 is characterized in that, the antibiotic of local application effective dose.
9. the method for claim 1 is characterized in that, described dispenser step is to pass through topical.
10. one kind contains packaging material and a certain amount of amino acid whose goods, it is characterized in that, described packaging material contain a label, and this label shows that described aminoacid is to be used for the treatment of the patient with acute wounds, and the described aminoacid of the described amount of local application is to promote the healing of described wound.
11. goods as claimed in claim 10 is characterized in that, described aminoacid is arginine.
12. goods as claimed in claim 10 is characterized in that, described aminoacid is ornithine.
13. goods as claimed in claim 10 is characterized in that, described aminoacid is leucine.
14. goods as claimed in claim 10 is characterized in that, described aminoacid is glutamic acid.
15. goods as claimed in claim 10 is characterized in that, described goods also contain topical anesthetic cream.
16. goods as claimed in claim 10 is characterized in that, described goods also contain anti-inflammatory agent.
17. goods as claimed in claim 10 is characterized in that, described goods are local application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031329640A CN1491645A (en) | 2002-10-24 | 2003-07-25 | Compound preparation for improving acute wound heeling for local use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02145652 | 2002-10-24 | ||
| CN02145652.6 | 2002-10-24 | ||
| CNA031329640A CN1491645A (en) | 2002-10-24 | 2003-07-25 | Compound preparation for improving acute wound heeling for local use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1491645A true CN1491645A (en) | 2004-04-28 |
Family
ID=34276041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031329640A Pending CN1491645A (en) | 2002-10-24 | 2003-07-25 | Compound preparation for improving acute wound heeling for local use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1491645A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920660A (en) * | 2016-05-25 | 2016-09-07 | 天津嘉氏堂医美科技有限公司 | Composition and preparation for treating chronic wounds |
| CN108653800A (en) * | 2018-06-06 | 2018-10-16 | 中国医学科学院生物医学工程研究所 | Containing bioactivity glass and/or arginic wound repair dressing and the preparation method and application thereof |
| CN113616846A (en) * | 2020-05-09 | 2021-11-09 | 中山大学附属第六医院 | Dressing for promoting skin wound healing and preparation method thereof |
-
2003
- 2003-07-25 CN CNA031329640A patent/CN1491645A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920660A (en) * | 2016-05-25 | 2016-09-07 | 天津嘉氏堂医美科技有限公司 | Composition and preparation for treating chronic wounds |
| CN108653800A (en) * | 2018-06-06 | 2018-10-16 | 中国医学科学院生物医学工程研究所 | Containing bioactivity glass and/or arginic wound repair dressing and the preparation method and application thereof |
| CN113616846A (en) * | 2020-05-09 | 2021-11-09 | 中山大学附属第六医院 | Dressing for promoting skin wound healing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5770582A (en) | Pharmaceutical compositions containing deoxyribonucleosides for wound healing | |
| JP3919212B2 (en) | Wound healing treatment for fibrosis | |
| US20090098061A1 (en) | Solution for tissue adhesion prevention and method for tissue adhesion prevention | |
| US8377468B2 (en) | Dry wound dressing and drug delivery system | |
| EP2815754B1 (en) | Composition for treating biofilm-based infections | |
| WO2008037262A1 (en) | Wound healing composition comprising phosphate, iron and copper | |
| EP1404281B1 (en) | Pharmaceutical compositions of topic use, applied in treatment of skin and/or mucous injuries; use of compositions in treatment of skin and/or mucous injuries and use of compounds in treatment of skin and/or mucous injuries | |
| KR100687781B1 (en) | Preparations for the application of anti-inflammatory agents | |
| JP2804846B2 (en) | New pharmaceutical composition for skin diseases | |
| DK176007B1 (en) | Pharmaceutical composition containing deoxyribonucleosides for wound healing | |
| US20030091601A1 (en) | Use of topical arginine to enhance wound healing | |
| JP2983335B2 (en) | Use of fosfomycin and its pharmaceutically acceptable salts as topical scar forming agents | |
| CN1491645A (en) | Compound preparation for improving acute wound heeling for local use | |
| CN1507860A (en) | Complex prescription preparation of local application for promoting chronic wound healing | |
| KR960700069A (en) | Wound Treatment Composition (WOUND HEALING COMPOSITION) | |
| EP4070783A1 (en) | Microspheres for the treatment of musculoskeletal and vascular skin or dermatological disorders | |
| WO2006022536A1 (en) | New medical use of the meldonium | |
| US6919320B1 (en) | Pharmaceutical compositions containing deoxyribonucleosides for wound healing | |
| RU2278689C2 (en) | Method for treatment of trophic ulcer and long-term open septic wound | |
| RU2381804C1 (en) | Ointment for treating burn diseases with albumin and propolis extract | |
| RU41613U1 (en) | DEVICE FOR TREATMENT OF TROPHIC ULCERS AND LONGLY HEALING FUSAL RAS | |
| US20230310538A1 (en) | Tissue repair and wound healing composition and method using low molecular weight hydrolyzed collagen | |
| US20240207351A1 (en) | Tissue repair and wound healing composition and method using low molecular weight hydrolyzed collagen | |
| RU2153352C1 (en) | Pharmaceutical composition showing wound-healing and anti-inflammatory effect | |
| Alexieva et al. | Diet Supplemented with Whey Protects Balb/c Mice from Indomethacin-Induced Gut Injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |